Northern Trust’s Evoke Pharma EVOK Stock Holding History

Northern Trust’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-293	Closed	-$21K	–	4762
2022 Q1	$21K	Hold	293	–	–	﹤0.01%	4666
2021 Q4	$23K	Hold	293	–	–	﹤0.01%	4696
2021 Q3	$55K	Hold	293	–	–	﹤0.01%	4520
2021 Q2	$58K	Hold	293	–	–	﹤0.01%	4465
2021 Q1	$77K	Buy	293 +38	+15%	+$15.2K	﹤0.01%	4328
2020 Q4	$95K	Sell	255 -4	-2%	-$2.06K	﹤0.01%	4123
2020 Q3	$175K	Sell	259 -1	-0.4%	-$638	﹤0.01%	3847
2020 Q2	$133K	Buy	260 +24	+10%	+$6.68K	﹤0.01%	3856
2020 Q1	$39K	Hold	236	–	–	﹤0.01%	3991
2019 Q4	$55K	Hold	236	–	–	﹤0.01%	4042
2019 Q3	$29K	Hold	236	–	–	﹤0.01%	4122
2019 Q2	$21K	Hold	236	–	–	﹤0.01%	4160
2019 Q1	$51K	Hold	236	–	–	﹤0.01%	4033
2018 Q4	$84K	Hold	236	–	–	﹤0.01%	3958
2018 Q3	$101K	Hold	236	–	–	﹤0.01%	4032
2018 Q2	$85K	Hold	236	–	–	﹤0.01%	4043
2018 Q1	$71K	Buy	236 +28	+13%	+$9.21K	﹤0.01%	4030
2017 Q4	$68K	Buy	208 +5	+2%	+$2.07K	﹤0.01%	4035
2017 Q3	$98K	Hold	203	–	–	﹤0.01%	3958
2017 Q2	$75K	Hold	203	–	–	﹤0.01%	4030
2017 Q1	$91K	Buy	+203	New	+$83.2K	﹤0.01%	3970

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Northern Trust's EVOK Position: Q2 2022 in Review

Northern Trust sold out of Evoke Pharma (EVOK) in Q2 2022, closing a stake of 293 shares — an estimated $21K sold.

Northern Trust first reported a position in EVOK in Q1 2017 and held it in 21 quarters. The position peaked at $175K in Q3 2020. 12 funds tracked by Wall St. Rank hold EVOK as of Q2 2022.

Northern Trust reported no remaining Evoke Pharma position as of Q2 2022 after selling out during the quarter.
Northern Trust sold 293 Evoke Pharma shares in Q2 2022, an estimated $21K.
Northern Trust first reported a position in Evoke Pharma in Q1 2017 and held it in 21 quarters.
Northern Trust's Evoke Pharma position peaked at $175K in Q3 2020.
12 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2022.

Based on Northern Trust's 13F filing for Q2 2022, filed 12 Aug 2022.